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Available online xxxxGenome-wide association studies (GWAS) have identiﬁed a locus on chromosome 1p21.3 to be highly associated
with schizophrenia. A microRNA, MIR137, within this locus has been proposed as the gene causally associated
with schizophrenia, due to its known role as a regulator of neuronal development and function. However, the in-
volvement of other genes within this region, including DPYD (dihydropyrimidine dehydrogenase), is also plau-
sible. In this communication, we describe a previously uncharacterised, brain-expressed RNA, EU358092,
within the schizophrenia-associated region at 1p21.3. As we observed for MIR137, EU358092 expression was
modulated in response to psychoactive drug treatment in the human SH-SY5Y neuroblastoma cell line. Bioinfor-
matic analysis of publically available CNS expression data indicates that MIR137 and EU358092 are often co-
expressed in vivo. A potential regulatory domain for expression of EU358092 is identiﬁed by bioinformatic anal-
ysis and its regulatory function is conﬁrmed by reporter gene assays. These data suggest a potentially important
role for EU358092 in the aetiology of schizophrenia, either individually or in combinationwith other genes at this
locus.






Chromosome 1p21.3 (chr1:98298371-98581337, GRCh37/hg19)
has consistently been associated with schizophrenia by genome-wide
association studies (GWAS) (Ripke et al., 2013; Ripke et al., 2011). Ef-
forts to understand the signiﬁcance of this locus have predominantly fo-
cused on the function of one of the geneswithin this locus, MIR137, and
to a lesser extent its neighbouring gene, DPYD (dihydropyrimidine de-
hydrogenase), which has also been implicated in a range of neurological
and psychiatric conditions (Carter et al., 2011; Prasad et al., 2012; Xu
et al., 2012). While these genes are the most obvious candidates for
causal association, it is important to consider the possibility that there
are additional unknown or uncharacterised brain-expressed RNAs at
this locus that may also contribute to schizophrenia susceptibility. To
address such a possibility, we performed bioinformatic analysis of the
locus, using the UCSC Genome Browser (http://genome.ucsc.edu/) to
overlay ENCODE (Encyclopaedia of DNA Elements) and GWAS data. In
this communication, we identify an RNA termed EU358092, which
shares many of the molecular and genetic characteristics previously at-
tributed to MIR137, both in vitro and in vivo. This study extends thend Clinical Pharmacology, The
UK.
. This is an open access article under
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Bioinformatic analysis was performed with the UCSC Genome
Browser, genome build GRCh37/hg19 (http://genome.ucsc.edu;
accessed 10/09/2015) and Evolutionary Conserved Region (ECR)
browser (http://ecrbrowser.dcode.org; accessed 01/03/2015) to identi-
fy ECRs of interest at theMIR137 locus. ECRs were deﬁned as reaching a
minimum of 70% homology when the human sequence was compared
to other species; this is the default setting of the programme. Schizo-
phrenia genome-wide SNP data from the ‘PGC_SCZ52_may13’ dataset
was accessed through Ricopili (http://www.broadinstitute.org/mpg/
ricopili/). Aceview, Human 2010 genome (http://www.ncbi.nlm.nih.
gov/IEB/Research/Acembly/index.html; accessed 10/09/2015) was
used to access RNA-seq data on EU35802 (named ‘jufobu’ in Aceview)
from the Non-Human Primate Reference Transcriptome Resource
(NHPRTR; http://nhprtr.org/).
LD analysis was performed using SNP genotype data from the CEU/
CEPH cohort (European descent) spanning chr1:98,105,779–
98,855,147 downloaded from the HapMap Genome Browser (http://
hapmap.ncbi.nlm.nih.gov/), release #28. LD analysis was performedthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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following parameters: Hardy-Weinberg p-value cut-off, 0.001; mini-
mum genotype cut-off, 75%; maximum number of Mendel errors, 1;
minimum minor allele frequency, 0.01) and pair-wise tagging analysis
performed (r2 threshold, 0.8). Haplotype blocks were determined
using 95% conﬁdence intervals (Gabriel et al., 2002).2.2. Plasmid construction
Two ECR domains at EU358092 (termed EU1 and EU2) were cloned
into the pGL3-Promoter (pGL3P) luciferase reporter vector (Promega).
EU1 and EU2 were ampliﬁed by PCR from pooled mixed gender
human genomic DNA preparations (Promega) using Phusion High-
Fidelity DNA Polymerase (New England Biolabs). Fragments were
cloned into the pGL3P vector using Gibson isothermal assembly (NEB
Gibson AssemblyMasterMix) as described in themanufacturer's proto-
col, and transformed into XL10-Gold ultracompetent cells (Agilent
Technologies) for ampliﬁcation and puriﬁcation.
Primers used to amplify each fragmentwere designed to include 16–
20 bp of vector DNA (underlined) ﬂanking the SmaI restriction enzyme
site for directional cloning into pGL3P. The following primer sets were
used:
EU1 ECR primers:
Forward – 5′ AGCTCTTACGCGTGCTAGTGTAGCGAACCAACTGT 3′.
Reverse – 5′ GCAGATCGCAGATCTCGAGTCAAGGCTTATTGTCTTTGG
3′.
EU2 ECR primers:
Forward – 5′ AGCTCTTACGCGTGCTAGAGGCTTCAATGAAAAGAG 3′.
Reverse – 5′ AGATCGCAGATCTCGAGTCATGTGTAATGTCCTGG 3′.2.3. Cell culture and drug treatments
SH-SY5Y neuroblastoma cell line (ATCC number CRL-2266) was
maintained in a 1:1 mix of Minimal Essential Medium Eagle (Sigma)
and NutrientMixture F-12 Ham (Sigma), supplementedwith 10% foetal
bovine serum (Sigma), 1% penicillin/streptomycin (100 U/ml,
100 mg/ml; Sigma), 1% (v/v) 200 mM L-glutamine (Sigma), and 1% (v/
v) 100 mM sodium pyruvate (Sigma). Cells were incubated at 37 °C
with 5% CO2.
Stock solutionsweremade for amphetamine, cocaine hydrochloride,
lithium chloride, and valproic acid sodium salt (Sigma) using sterile ﬁl-
tered dH2O, and diluted as appropriate in SH-SY5Y media. Cells were
cultivated for 24 h, before a 1 h incubation with either: vehicle control
(sterile ﬁltered dH2O), 10 μM amphetamine (Jones and Kauer, 1999;
Shyu et al., 2004), 10 μM cocaine (Warburton et al., 2015c), 1 mM lith-
ium (Hing et al., 2012; Roberts et al., 2007) or 5 mM sodium valproate
(Pan et al., 2005; Phiel et al., 2001; Zhang et al., 2003). For each drug
treatment, n=4. Cells were harvested directly after the 1 h drug treat-
ment for RNA extraction.2.4. Cell culture and luciferase reporter Gene assays
SH-SY5Y cells were seeded at approximately 100,000 cells per well
and transfected with 1 μg plasmid DNA and 10 ng pMLuc2 (Novagen)
(internal control) using TurboFect (Thermo Scientiﬁc). Transfected
cells were processed 48 h post-transfection using the Dual-Luciferase
Reporter Assay System (Promega). Dual luciferase assays were per-
formed by a Glomax™ 96 Microplate Luminometer (Promega), accord-
ing to manufacturer's instructions. Fold changes in ﬁreﬂy luciferase
activity (normalized to renilla luciferase activity) supported by the
EU358092 ECRs over the pGL3P controls were calculated and signiﬁ-
cance determined using two-tailed t-tests. Signiﬁcance was scored as
follows: *P b 0.05, **P b 0.01, ***P b 0.001. For each transfection, n= 4.Please cite this article as: Gianfrancesco, O., et al., Novel brain expressed RN
Res. (2016), http://dx.doi.org/10.1016/j.schres.2016.11.0342.5. In vitro RNA extraction
Total RNA was extracted from SH-SY5Y cells using Trizol reagent
(Invitrogen) following manufacturer's protocol. The resulting RNA pel-
lets were resuspended in RNase-free water, and 500 ng reverse tran-
scribed into cDNA using the GoScript™ RT system (Promega).
For analysis of gene expression, cDNA was ampliﬁed using GoTaq
DNA polymerase (Promega) following manufacturer's guidelines,
using undiluted cDNA for target genes and a 1:200 dilution for the ref-
erence gene.
PCRwas performed in a thermocyclerwith the following conditions:
incubation at 95 °C for 5 min, followed by 35 cycles of: (i) 95 °C for 30 s,
(ii) 60 °C for 30 s, (iii) 72 °C for 30 s, with a ﬁnal cycle at 72 °C for 10min.
Primers used to amplify EU358092:
Forward – 5′ GGTGGGAATTGGGTCTCACA 3′.
Reverse−5′ GATGAACCTTGACAACGCTGTGTTAAG 3′.
Primers used to amplify actin B control:
Forward – 5′ CACCCCTACAATGAGCTGCGTGTG 3′.
Reverse – 5′ ATAGCACAGCCTGGATAGCAACGTAC 3′.
3. Results
3.1. Bioinformatic analysis of the MIR137 locus identiﬁes regions of
conservation and transcriptional activity
Identiﬁcation of non-coding evolutionary conserved regions (ECRs)
at theMIR137 locus is likely to highlight important functional domains,
such as transcriptional or post-transcriptional regulatory elements, in
addition to other RNAs. Our analysis, using both the UCSC and ECR ge-
nome browsers, identiﬁed ECRs between DPYD and MIR137
(chr1:98,395,390–98,407,578; GRCh37/hg19) (Fig. 1). These were
within the schizophrenia-associated region identiﬁed by GWAS
(Fig. 1a). Further analysis of this region using GenBank and ENCODE
data identiﬁed an uncharacterised, brain-expressed transcript named
EU358092, overlapping one of the ECRs at this locus, as well as active
H3K27Ac histone marks (Fig. 1b) and transcription factor binding se-
quences (data not shown). In addition, there were schizophrenia
GWAS SNPs across the EU358092 RNA sequence (Fig. 2a), and SNPs at
this region in LD with schizophrenia GWAS SNPs in the larger locus
(Fig. 2b).
3.2. Bioinformatic data supports long non coding RNA (lncRNA) status of
EU358092
A range of bioinformatic information, accessed through the UCSC
Genome Browser, provided support for EU358092 as a lncRNA (long
non-coding RNA). GenBank and AceView data listed EU358092 as a
human, brain-expressed 869 bp mRNA, having been detected in the
amygdala and foetal brain. Current data indicated that this RNA
had two exons and covered a genomic distance of 8.27 kb
(chr1:98,399,030–98,407,302; GRCh37/hg19) (Fig. 2a). This is consis-
tent with analysis by Derrien et al. on the GENCODE collection of
14,880 lncRNAs which showed that 98% were spliced and 42% were
two exon transcripts (Derrien et al., 2012). Analysis of the potential pro-
tein coding capacity of the EU358092 sequence by the ExPASy transla-
tion tool (http://web.expasy.org/translate/) demonstrated that there
are many stop codons in every frame, with the longest open reading
frame being 72 amino acids (data not shown).
While MIR137 is clearly an important gene at this locus, EU358092
shares a number of equally important attributes thatwarrant further in-
vestigation. For example, using the UCSC Genome Browser's Multiz 100
vertebrate genome alignment tool, the exons of EU358092were shown
to be conserved to the same degree as the second exon of the MIR137
short transcript, AK311400, exons 3 and 4 of the long MIR137HG tran-
script, and the second MIR137 locus microRNA, MIR2682 (Fig. 1a).A identiﬁed at theMIR137 schizophrenia-associated locus, Schizophr.
Fig. 1. Chromosome 1p21.3 genome wide schizophrenia-associated locus. (a) A composite ﬁgure overlaying data across the MIR137 and DPYD genes at chr1:98,300,000–98,600,000
(GRCh37/hg19). The Psychiatric Genomics Consortium's May 2013 schizophrenia GWAS data (PGC SCZ52) was overlaid with H3K27Ac histone marks and evolutionary conservation
data from the UCSC Genome Browser. Points above the green line represent GWAS SNPs with a statistically signiﬁcant P-value of 5.0 × 10−8 or more, demonstrating high genome-
wide association for schizophrenia across the locus, which expands from MIR137 into EU358092 and the neighbouring gene, DPYD. Evolutionary conservation and H3K27Ac marks
over this locus are shown below, and are markers of potential conserved function and active transcriptional regulation, respectively. The region encompassing EU358092 is boxed and
expanded in (b). (b) The EU358092 boxed region in (a) is expanded, showing more clearly the peak of H3K27Ac histone modiﬁcations, and presenting sequence comparison between
multiple species, identifying two evolutionary conserved regions which are displayed as peaks named EU1 and EU2. EU1 overlaps the ﬁrst exon of EU358092, and EU2 is approximately
2.6 kb upstream of the predicted transcriptional start site of EU358092. The locations of EU1 and EU2 indicate that they may exert regulatory effects on the EU358092 promoter.
3O. Gianfrancesco et al. / Schizophrenia Research xxx (2016) xxx–xxxOverall, human EU358092 is 97.2% conserved in the rhesusmacaque ge-
nome, with 86.1% conservation back to mouse.
3.3. GWAS and LD support role for EU358092 in schizophrenia
The Psychiatric Genomics Consortium's 2013 schizophrenia GWAS
data (PGC2, available at: https://www.med.unc.edu/pgc) listed 16
schizophrenia GWAS SNPs across the EU358092 transcript and its up-
stream ECR, as shown in Fig. 2a. Two schizophrenia associated SNPs
(rs4294451 and rs4378243) fromwithin the 1p21.3 regionwere within
or directly adjacent to EU358092 ECR 2 (EU2), a potential regulatory el-
ement for EU358092. HaploView v4.2 was used to carry out LD analysis
of SNPs at the EU358092 locus based on SNP genotype data from thePlease cite this article as: Gianfrancesco, O., et al., Novel brain expressed RN
Res. (2016), http://dx.doi.org/10.1016/j.schres.2016.11.034HapMap CEU cohort. Data for seven of the 16 schizophrenia associated
SNPs was available in this HapMap cohort, while the remaining non-
GWAS HapMap SNPs were included but lacked sufﬁcient data to assess
LD (Fig. 2b). Three SNPs at the MIR137 major and internal promoters
were also incorporated into this analysis, including the schizophrenia
GWAS SNP, rs2660304, which resides at the internal MIR137 promoter,
and which we have previously shown to support differential allele-
speciﬁc expression (Warburton et al., 2015a).
LD analysis showed that six of the seven EU358092 schizophrenia
GWAS SNPs tested were in complete LD with each other, and formed
a haplotype blockwhich spanned theMIR137 transcript, including com-
plete (D′ = 1) or strong (D′ ≥ 0.85) LD with the MIR137 internal pro-
moter SNP. The remaining schizophrenia associated SNP at this locusA identiﬁed at theMIR137 schizophrenia-associated locus, Schizophr.
Fig. 2. Linkage disequilibrium (LD) analysis of SNPs across the EU358092 locus. (a) Schematic representation of the EU358092 locus and identiﬁed ECRs, in relation to 16 schizophrenia
GWAS SNPs across this locus. Two schizophrenia GWAS SNPs (rs4294451 and rs4378243) are within EU358092 ECR 2 (EU2), and may therefore modify the function of this conserved
element, or tag this as a region of functional interest. (b) LD analysis of SNPs at EU358092 was carried out using SNP genotype data from the HapMap CEU cohort with D′ values. Data
for seven of the 16 schizophrenia GWAS SNPs (starred*) was available in this HapMap cohort. The remaining non-GWAS HapMap SNPs were included in the above plot, however the
minor allele frequency data for these SNPs was not sufﬁcient to assess LD. All schizophrenia GWAS SNPs at this locus, with the exception of the EU359082 splice site SNP rs12741167,
were in complete LD and form a haplotype block as deﬁned by Gabriel et al. (Gabriel et al., 2002). The schizophrenia GWAS SNPs at EU358092 were in LD with the schizophrenia
GWAS SNP rs2660304 at the MIR137 internal promoter. The functional signiﬁcance of the GWAS across this locus may be highlighting either EU358092 or MIR137, which may be
acting separately or synergistically to inﬂuence the association across this locus with schizophrenia.
4 O. Gianfrancesco et al. / Schizophrenia Research xxx (2016) xxx–xxxwith available data, rs12741167, was directly at the annotated splice
site of EU358092, and was in partial LD with the other GWAS SNPs at
this locus (Fig. 2b). This arrangement of schizophrenia GWAS SNPs in
a haplotype block spanning EU358092 and MIR137 may suggest that
schizophrenia risk at this locus ismediated through relatedmechanisms
on multiple targets.3.4. Expression of EU358092 in vivo
Expression of EU358092 in vivo across primate species was com-
pared to MIR137 and DPYD by analysis of RNA-seq data from the Non-
Human Primate Reference Transcriptome Resource (NHPRTR, accessed
via AceView). EU358092 (termed ‘jufobu’ in this database) displayed a
similar expression pattern to that of MIR137, with highest expression
restricted to the brain and pituitary gland, whereas DPYD was foundPlease cite this article as: Gianfrancesco, O., et al., Novel brain expressed RN
Res. (2016), http://dx.doi.org/10.1016/j.schres.2016.11.034to be expressed at high levels across themajority of tissues in all primate
species tested (Supplementary Fig. 1).
To further address EU358092 expression speciﬁcally in humans, we
used UCSC Genome Browser to access the Sestan Lab microarray ex-
pression data from four human late mid-foetal brains (Johnson et al.,
2009). At this time-point, EU358092 expressionwas observed in the or-
bital prefrontal, medial prefrontal, parietal, temporal association and
temporal auditory cortices (Fig. 3a). Similarly, brain microarray data
showed MIR137 expression across regions of the prefrontal cortex, in-
cluding the medial, dorsolateral, and ventrolateral regions, as well as
being most highly expressed in the temporal association and temporal
auditory cortices (Fig. 3b). Neither EU358092 nor MIR137 were found
to be expressed in the thalamus or cerebellum. The broadly similar ex-
pression patterns of EU358092 and MIR137 may suggest co-ordinated
expression of both RNAs, and point to an as yet undetermined brain-
related function for EU358092 (Fig. 3).A identiﬁed at theMIR137 schizophrenia-associated locus, Schizophr.
Fig. 3. Comparison of MIR137 and EU358092 expression in vivo. (a) Sestan lab brain microarray expression data (accessible through UCSC Genome Browser) for EU358092 showed
expression (red) in the orbital and medial prefrontal cortices, as well as the parietal, temporal association and temporal auditory cortices. No expression (blue) of EU358092 was seen
in the hippocampus, striatum, thalamus, or cerebellum. (b) Brain microarray data showed MIR137 expression across regions of the prefrontal cortex, including the medial,
dorsolateral, and ventrolateral regions, as well as being most highly expressed in the temporal association and temporal auditory cortices. MIR137 was not found to be expressed in
the thalamus or cerebellum. The similar expression patterns of EU358092 and MIR137 across brain regions may suggest a co-ordinated pattern of expression for genes at this locus,
pointing to a potentially important brain-related function for EU358092.
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EU358092 expressionwas conﬁrmed in vitro in SH-SY5Y neuroblas-
toma cells (Fig. 4a). We have previously demonstrated that expression
of MIR137 in this cell line was inducible by drug action (Warburton
et al., 2015b).We therefore compared EU358092 expression under sim-
ilar conditions, after 1 h treatment with lithium chloride (1 mM), sodi-
um valproate (5 mM), cocaine (10 μM), and amphetamine (10 μM)
(Fig. 4a). EU358092 was regulated in response to psychoactive com-
pounds, with an increase in expression after 5 mM sodium valproate
treatment, and a strong decrease after 10 μM cocaine treatment
(Fig. 4a); this was analogous to our previous data on MIR137.
To conﬁrm our hypothesis that the ECR adjacent to EU358092,
termed EU2,might have transcriptional regulatory properties,we tested
both EU2 and EU1 (which corresponds to exon 1 of EU358092) inPlease cite this article as: Gianfrancesco, O., et al., Novel brain expressed RN
Res. (2016), http://dx.doi.org/10.1016/j.schres.2016.11.034reporter gene constructs in SH-SY5Y neuroblastoma cells. EU2, posi-
tioned approximately 2.6 kb upstream of the predicted EU358092 tran-
scriptional start site, supported a 2.12-fold increase in reporter gene
expression (p = 7.97 × 10−4) in the SH-SY5Y cell line (Fig. 4b). This
ECR also contained the schizophrenia GWAS SNP rs4378243,with a sec-
ond schizophrenia GWAS SNP (rs4294451) 25 bp from the boundary of
the ECR used in our assay. EU1 had no effect on the baseline expression
of the reporter gene (p=0.90). Taken together, these results suggested
a regulatory role for EU2, and were consistent with EU1 encoding the
ﬁrst exon of the RNA, rather than constituting a regulatory domain.
4. Discussion
GWAS has identiﬁed the MIR137/DPYD locus on chromosome
1p21.3 as being strongly associated with schizophrenia. The locationA identiﬁed at theMIR137 schizophrenia-associated locus, Schizophr.
Fig. 4. Activity of the EU358092 locus in vitro. (a) Expression of EU358092 was addressed
in vitro by PCR of cDNA from SH-SY5Y under basal conditions, and after the following
treatments: lithium chloride (1 mM), sodium valproate (5 mM), cocaine (10 μM), and
amphetamine (10 μM). Actin B was used as an internal control. EU358092 was shown to
be expressed under basal conditions in SH-SY5Y neuroblastoma cells, with expression
upregulated following treatment with sodium valproate, and strongly downregulated
following cocaine treatment. This pattern of expression in response to challenge was
also seen for MIR137 (Warburton et al., 2015b) and may suggest related regulatory
responses of transcripts at this locus. (b) Regulatory function of ECR sequences was
assessed by dual luciferase assay in the pGL3-Promoter (pGL3P) vector in SH-SY5Y
neuroblastoma cells under basal conditions. EU358092 ECR 2 (EU2) supported a 2.12-
fold increase in reporter gene expression compared to baseline expression from the
empty pGL3P vector, supporting a regulatory role for this sequence, which may act upon
the EU358092 promoter to modulate gene expression. EU1 displayed no regulatory
function in this assay, which is consistent with this region displaying evolutionary
conservation because it encodes the ﬁrst exon of the EU358092 transcript, rather than
being a conserved regulatory element. N= 4; ***p b 0.001.
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coding regions of DPYD suggest that a regulatory mechanismmight op-
erate at this locus that could result in modulation of expression of these
genes. As a microRNA, MIR137 will modulate multiple mRNA targets,
with consequences at the protein level. These targets have been postu-
lated to include transcripts from many schizophrenia associated genes,
such as CACNA1C, and thus MIR137 has been highlighted as a potential
modulator of CNS function that could reveal underlying schizophrenia
biology. We have previously used bioinformatic and functional genetics
to address differential regulation of MIR137 (Warburton et al., 2015a;
Warburton et al., 2015b). In this communicationwe have used a similar
strategy to highlight the potential involvement of the RNA EU358092 in
schizophrenia.
We demonstrated that EU358092 was as conserved as MIR137
(Fig. 1) and that themRNAwas tagged bymany SNPs signiﬁcantly asso-
ciated with schizophrenia by GWAS over the locus (Fig. 2). Analysis of
its expression in vivo in the CNS (Figs. 3 and Supplementary Fig. 1)
suggested co-expression of EU358092 and MIR137 in many cells. Stim-
ulus inducible expression of EU358092 in response to drug challenge
was demonstrated in vitro in SH-SY5Y neuroblastoma cells, which
was again similar to previous expression patterns observed for
MIR137 (Fig. 4), consistent with both RNAs responding to related
transcriptional cues.
EU358092 has many of the characteristics of a non-coding RNA of
the lncRNA class. Whilst little is known regarding the function of
lncRNAs compared to microRNAs, they are a major class of non-coding
transcripts, deﬁned as RNAs of N200 nucleotides in length which lack
protein coding potential. Although only a small fraction (b2%) of the
human genome encodes proteins, the majority of the human genome
is capable of being transcribed (Djebali et al., 2012). The 2012Please cite this article as: Gianfrancesco, O., et al., Novel brain expressed RN
Res. (2016), http://dx.doi.org/10.1016/j.schres.2016.11.034GENCODE v7 release collected 14,880 annotated human lncRNAs
(Derrien et al., 2012), yet they remain poorly understood despite their
abundance. They often display tissue-speciﬁc expression patterns and
are thought to function as regulators of gene expression through a
broad array of mechanisms (Spadaro et al., 2015; Ulitsky and Bartel,
2013). LncRNAs are increasingly being found to play roles in
neurodevelopmental, neurodegenerative, and psychiatric disorders.
For example, over 200 differentially expressed lncRNAs have been iden-
tiﬁed in the brains of individuals with autism spectrum disorder (ASD),
which were enriched at genomic loci containing genes linked to
neurodevelopment or psychiatric disorders (Ziats and Rennert, 2013).
LncRNAs have also been proposed to play a role in schizophrenia, and
as such their transcriptional regulation is of paramount importance
(Butler et al., 2016; van de Vondervoort et al., 2013). This is consistent
with the ﬁndings of Liao et al., who demonstrated epigenetic (methyla-
tion) differences over lncRNAs in schizophrenia (Liao et al., 2015), and
work by Ren et al. which showed modulation of lncRNA networks in
early onset schizophrenia (Ren et al., 2015). More speciﬁcally, genetic
variants of the lncRNAMIAT (also termed Gomafu) have been associat-
ed with paranoid schizophrenia in the Han Chinese population (Rao
et al., 2015). This lncRNA has been shown to modulate expression of
genes involved in schizophrenia such as CSMD1 (Steen et al., 2013)
andDISC1 (Barry, 2014). Our studywould add another potential lncRNA
target for consideration as a modulator of the CNS transcriptome in
schizophrenia. Speciﬁcally, EU358092 demonstrated many of the char-
acteristics of MIR137 with regard to genetic association and expression
in vivo and in vitro. The function of EU359092 was outside the scope of
our study, but it should be of interest to those addressing schizophrenia.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.schres.2016.11.034.
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